open access

Vol 19, No 5 (2012)
Original articles
Published online: 2012-10-06
Get Citation

Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?

Marek Postula, Marek Rosiak, Agnieszka Kaplon-Cieslicka, Agnieszka Kondracka, Ewa Trzepla, Krzysztof J. Filipiak, Andrzej Czlonkowski, Grzegorz Opolski
DOI: 10.5603/CJ.2012.0090
·
Cardiol J 2012;19(5):494-500.

open access

Vol 19, No 5 (2012)
Original articles
Published online: 2012-10-06

Abstract


Background: Type 2 diabetes (T2DM) patients are at increased risk of cardiovascular events despite long-term acetylsalicylic acid (ASA) therapy. This study was performed to establish the prevalence of high platelet reactivity (HPR) on ASA in T2DM and to identify its predictors.
Methods: The study included 185 T2DM on chronic ASA therapy and to assess platelet reactivity during long-term ASA therapy, we applied the point-of-care method VerifyNow® aspirin test (Accumetrics, San Diego, CA, USA).
Results: Compared with the low platelet reactivity (LPR) group, patients with HPR had higher triglyceride levels (145 vs. 118 mg/dL, p = 0.041), were less frequently treated with statins (57.1% vs. 75.3%; p = 0.038) and tumor necrosis factor-alpha (TNF-α) concentrations were higher (2.15 vs. 1.74 pg/mL; p = 0.052). In a multivariate analysis only statin therapy (OR 0.375; 95% CI 0.15-0.91; p = 0.030) and lower concentrations of TNF-α (for each 1.0 pg/mL: OR 1.3; 95% CI 1.00-1.72; p = 0.046) were predictive of LPR.
Conclusions: Our study provides indirect evidence that the beneficial effect of statins on platelet activity may be related to their non-lipid-mediated, pleiotropic mechanisms of action. This might have been partly related to decreased platelet reactivity in patients receiving statin therapy. In our study in patients with T2DM, platelet reactivity on ASA therapy measured with VerifyNow® was associated with TNF-α concentrations and statin therapy. These results may imply a role for subclinical systemic inflammation and a beneficial effect of statins in the development of HPR in T2DM. (Cardiol J 2012; 19, 5: 494-500)

Abstract


Background: Type 2 diabetes (T2DM) patients are at increased risk of cardiovascular events despite long-term acetylsalicylic acid (ASA) therapy. This study was performed to establish the prevalence of high platelet reactivity (HPR) on ASA in T2DM and to identify its predictors.
Methods: The study included 185 T2DM on chronic ASA therapy and to assess platelet reactivity during long-term ASA therapy, we applied the point-of-care method VerifyNow® aspirin test (Accumetrics, San Diego, CA, USA).
Results: Compared with the low platelet reactivity (LPR) group, patients with HPR had higher triglyceride levels (145 vs. 118 mg/dL, p = 0.041), were less frequently treated with statins (57.1% vs. 75.3%; p = 0.038) and tumor necrosis factor-alpha (TNF-α) concentrations were higher (2.15 vs. 1.74 pg/mL; p = 0.052). In a multivariate analysis only statin therapy (OR 0.375; 95% CI 0.15-0.91; p = 0.030) and lower concentrations of TNF-α (for each 1.0 pg/mL: OR 1.3; 95% CI 1.00-1.72; p = 0.046) were predictive of LPR.
Conclusions: Our study provides indirect evidence that the beneficial effect of statins on platelet activity may be related to their non-lipid-mediated, pleiotropic mechanisms of action. This might have been partly related to decreased platelet reactivity in patients receiving statin therapy. In our study in patients with T2DM, platelet reactivity on ASA therapy measured with VerifyNow® was associated with TNF-α concentrations and statin therapy. These results may imply a role for subclinical systemic inflammation and a beneficial effect of statins in the development of HPR in T2DM. (Cardiol J 2012; 19, 5: 494-500)
Get Citation

Keywords

acetylsalicylic acid; platelet reactivity; statins; tumor necrosis factor- -alpha; coronary artery disease

About this article
Title

Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?

Journal

Cardiology Journal

Issue

Vol 19, No 5 (2012)

Pages

494-500

Published online

2012-10-06

DOI

10.5603/CJ.2012.0090

Bibliographic record

Cardiol J 2012;19(5):494-500.

Keywords

acetylsalicylic acid
platelet reactivity
statins
tumor necrosis factor- -alpha
coronary artery disease

Authors

Marek Postula
Marek Rosiak
Agnieszka Kaplon-Cieslicka
Agnieszka Kondracka
Ewa Trzepla
Krzysztof J. Filipiak
Andrzej Czlonkowski
Grzegorz Opolski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl